Drug Information

Drug General Information
Drug ID
D05GBE
Former ID
DNC012265
Drug Name
3-(Octahydro-quinolizin-3-yl)-phenol
Drug Type
Small molecular drug
Indication Discovery agent Investigative [530318]
Structure
Download
2D MOL

3D MOL
Formula
C15H21NO
Canonical SMILES
C1CCN2CC(CCC2C1)C3=CC(=CC=C3)O
InChI
1S/C15H21NO/c17-15-6-3-4-12(10-15)13-7-8-14-5-1-2-9-16(14)11-13/h3-4,6,10,13-14,17H,1-2,5,7-9,11H2
InChIKey
GBPVZNJTTUIKKY-UHFFFAOYSA-N
PubChem Compound ID
13720748
Target and Pathway
Target(s) D(2) dopamine receptor Target Info Inhibitor [530318]
KEGG Pathway Rap1 signaling pathway
cAMP signaling pathway
Neuroactive ligand-receptor interaction
Gap junction
Dopaminergic synapse
Parkinson's disease
Cocaine addiction
Alcoholism
PANTHER Pathway Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
Dopamine receptor mediated signaling pathway
Nicotine pharmacodynamics pathway
Reactome Dopamine receptors
G alpha (i) signalling events
WikiPathways Hypothetical Network for Drug Addiction
Monoamine GPCRs
GPCRs, Class A Rhodopsin-like
Genes and (Common) Pathways Underlying Drug Addiction
GPCR ligand binding
GPCR downstream signaling
Nicotine Activity on Dopaminergic Neurons
References
Ref 530318J Med Chem. 1990 Mar;33(3):1015-22.Pre- and postsynaptic dopaminergic activities of indolizidine and quinolizidine derivatives of 3-(3-hydroxyphenyl)-N-(n-propyl)piperidine (3-PPP). Further developments of a dopamine receptor model.
Ref 530318J Med Chem. 1990 Mar;33(3):1015-22.Pre- and postsynaptic dopaminergic activities of indolizidine and quinolizidine derivatives of 3-(3-hydroxyphenyl)-N-(n-propyl)piperidine (3-PPP). Further developments of a dopamine receptor model.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.